https://www.cancernetwork.com/view/fda-approval-of-essential-thrombocythemia-drug-is-important-milestone-2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/343ba667c5981a41ff62a56bf179583542af2942-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404434160112 https://www.cancernetwork.com/view/will-ai-steer-oncologists-or-will-oncologists-steer-ai-2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/7ff751bd8133c8e5d40e0b26dcab502be3a0aa60-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404036421112 https://www.cancernetwork.com/view/what-does-personalization-of-radiopharmaceutical-therapy-require-2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8a155caf320fe4d637bae016bde3507f25e4662e-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404201574112 https://www.cancernetwork.com/view/overlapping-toxicities-and-long-term-survivorship-needs2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404440458112 https://www.cancernetwork.com/view/oral-adherence-and-access-in-long-term-targeted-therapy2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404439085112 https://www.cancernetwork.com/view/preparing-patients-for-bispecific-antibody-based-first-line-therapy2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404438958112 https://www.cancernetwork.com/view/supporting-patients-when-first-line-therapy-intensifies2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404440457112 https://www.cancernetwork.com/view/managing-diarrhea-and-nutrition-on-first-line-egfr-therapy2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404439671112 https://www.cancernetwork.com/view/grading-toxicity-and-preserving-dose-intensity-in-nsclc2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404440170112 https://www.cancernetwork.com/view/telephone-triage-and-early-recognition-of-pneumonitis2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404440635112 https://www.cancernetwork.com/view/structuring-caregiver-education-at-treatment-initiation2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404439270112 https://www.cancernetwork.com/view/preventing-and-managing-dermatologic-toxicity-in-egfr-mutated-nsclc2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404440059112 https://www.cancernetwork.com/view/case-discussion-selecting-bcma-bispecific-therapy-for-a-patient-with-relapsed-refractory-multiple-myeloma-and-limited-access-to-car-t2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402776484112 https://www.cancernetwork.com/view/debate-the-future-role-of-bcma-bispecific-antibodies-in-later-line-relapsed-refractory-multiple-myeloma2026-09-02https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402777551112 https://www.cancernetwork.com/view/what-do-clinicians-get-right-about-radiopharmaceutical-therapy-2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d92b3c08052534d4964a6279055e163385639f6a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404199093112 https://www.cancernetwork.com/view/capivasertib-and-emerging-options-in-the-post-cdk4-6-inhibitor-setting2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404142929112 https://www.cancernetwork.com/view/managing-adverse-events-with-capivasertib-plus-fulvestrant2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404143194112 https://www.cancernetwork.com/view/survival-after-prior-cdk4-6-inhibition-and-delaying-chemotherapy2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404142807112 https://www.cancernetwork.com/view/post-progression-therapy-crossover-and-interpreting-survival-endpoints2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404143874112 https://www.cancernetwork.com/view/final-overall-survival-results-in-the-intention-to-treat-population2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404143385112 https://www.cancernetwork.com/view/final-overall-survival-in-the-pik3ca-akt1-pten-altered-population2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404143384112 https://www.cancernetwork.com/view/statistical-design-of-the-capitello-291-final-survival-analysis2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404143195112 https://www.cancernetwork.com/view/primary-progression-free-survival-results-from-capitello-2912026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404144270112 https://www.cancernetwork.com/view/capitello-291-study-design-and-intermittent-capivasertib-dosing2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404142930112 https://www.cancernetwork.com/view/how-is-ai-monitoring-inpatient-risk-and-reducing-documentation-burden-2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/924787367c00b9836720dbbae1d156d7d68a834a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404034268112 https://www.cancernetwork.com/view/no-new-safety-signals-seen-with-v940-plus-pembrolizumab-in-melanoma2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/4aed12e3c812ab3ba83f220e9c0e7099d7609442-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404030662112 https://www.cancernetwork.com/view/finding-support-through-the-relapsed-refractory-multiple-myeloma-journey2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403598491112 https://www.cancernetwork.com/view/multidisciplinary-support-in-relapsed-refractory-multiple-myeloma2026-09-01https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403597532112 https://www.cancernetwork.com/view/biomarker-testing-and-treatment-selection-in-hr-her2-mbc2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404385055112 https://www.cancernetwork.com/view/second-line-treatment-considerations-in-hr-her2-mbc2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/896dcfc5c9d747d7a3dbc3f2c5b5dfd59836f951-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404382794112 https://www.cancernetwork.com/view/navigating-molecular-testing-workflow-and-turnaround-time-in-nsclc2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/767eb7ff2e49c2ee2198847a60b02456e347745a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404376032112 https://www.cancernetwork.com/view/distinguishing-her2-mutation-from-amplification-and-overexpression-in-nsclc2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/767eb7ff2e49c2ee2198847a60b02456e347745a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404377099112 https://www.cancernetwork.com/view/from-wish-list-to-reality-ai-tools-already-working-in-matasar-s-practice2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/25cb48b08a6f8fd87e563871c7cb566719fa9f21-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404035828112 https://www.cancernetwork.com/view/v940-plus-pembrolizumab-cuts-melanoma-recurrence-risk-by-49-2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/85ea4698915849585d84080d293cbec67bc75dd0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404031049112 https://www.cancernetwork.com/view/proactive-patient-education-across-first-line-egfr-regimens2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404215014112 https://www.cancernetwork.com/view/baseline-nursing-assessment-before-first-line-egfr-therapy2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/0236bc763f7a8f5c55fbfeb706aba0dfc29f52d0-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404214419112 https://www.cancernetwork.com/view/keynote-966-long-term-follow-up-and-comparative-safety-of-chemoimmunotherapy2026-08-31https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c7a8b7d8cc2f7826679acabaa26445fe9d8d8d2-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403338409112 https://www.cancernetwork.com/view/is-digital-pathology-ready-to-transform-hematologic-diagnosis-2026-08-30https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9a67ca2d64cf979dca7b574e60ee80d14d9a436c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404034945112 https://www.cancernetwork.com/view/how-can-oncologists-start-experimenting-with-ai-tools-today-2026-08-29https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a5a4f0628f2225aac79b1777da286ad15d4b8cf4-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404035933112 https://www.cancernetwork.com/view/how-v940-works-mechanism-of-the-personalized-melanoma-vaccine2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/e9ff09cabe35088906e02e013751c00b7002e26e-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404029985112 https://www.cancernetwork.com/view/how-is-ai-already-being-used-in-blood-cancer-tumor-boards-2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a8d053b56d7246c952603f531197126ef18cb96d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404035933112 https://www.cancernetwork.com/view/individualizing-car-t-cell-therapy-vs-bispecific-antibodies-in-relapsed-multiple-myeloma2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404203735112 https://www.cancernetwork.com/view/where-ciltacabtagene-autoleucel-belongs-in-sequencing2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bdd3ddf809bee6fd691f5171ec241ab17a25cf2d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404203518112 https://www.cancernetwork.com/view/celmod-mechanism-and-differentiation-from-imids-in-multiple-myeloma2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fe82f7f4ac35486c484a02403932764cecd8188f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404153254112 https://www.cancernetwork.com/view/pi3k-akt-pathway-biology-capivasertib-and-biomarker-testing2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404142111112 https://www.cancernetwork.com/view/evolving-post-cdk4-6-inhibitor-landscape-in-advanced-breast-cancer2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9d6e12736330ce57d34dcda375ab93eae42e204c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404142928112 https://www.cancernetwork.com/view/managing-multifocal-bclc-c-hcc-with-portal-vein-invasion-and-variceal-history2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cabf8c772800a6812c20411dc26c291b2ee759d7-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6399918431112 https://www.cancernetwork.com/view/introduction-and-overview-of-celmods-in-multiple-myeloma2026-08-28https://cdn.sanity.io/images/0vv8moc6/cancernetwork/fe82f7f4ac35486c484a02403932764cecd8188f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404154828112 https://www.cancernetwork.com/view/matthew-matasar-md-lymphoma-specialist-navigating-the-immunotherapy-era2026-08-27https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9f375f92395c84101b17cedcee0f44e5cb202d4c-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6404036516112 https://www.cancernetwork.com/view/where-do-celmods-fit-with-car-t-cells-and-bispecifics-in-multiple-myeloma-2026-08-27https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ed8528aaaafbc9b60574836497759bc1738b5431-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403960315112 https://www.cancernetwork.com/view/biomarker-independent-adc-rina-s-advances-to-phase-3-in-endometrial-cancer2026-08-26https://cdn.sanity.io/images/0vv8moc6/cancernetwork/73c4df73e75a6dbd450f087797cde3e972979c89-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403604690112 https://www.cancernetwork.com/view/adaptive-planning-trial-aims-improve-radiosurgery-precision-brain-metastases2026-08-26https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f330793d8c76f4695d28201667fd74de51814577-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403661291112 https://www.cancernetwork.com/view/celmod-wins-landmark-approval-in-relapsed-refractory-multiple-myeloma2026-08-26https://cdn.sanity.io/images/0vv8moc6/cancernetwork/175f083d0013dfb309a007f55d72a7c70a75710f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403960316112 https://www.cancernetwork.com/view/debate-class-effect-versus-meaningful-differences-among-bcma-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma2026-08-26https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402776582112 https://www.cancernetwork.com/view/debate-car-t-cell-therapy-versus-bcma-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma2026-08-26https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402777645112 https://www.cancernetwork.com/view/the-importance-of-multidisciplinary-tumor-boards-in-brain-metastases-care2026-08-25https://cdn.sanity.io/images/0vv8moc6/cancernetwork/53d6ff38be0d93855223a0291f3aaf731ff6f448-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403811414112 https://www.cancernetwork.com/view/lenvatinib-dose-reductions-help-sustain-therapy-in-endometrial-cancer2026-08-25https://cdn.sanity.io/images/0vv8moc6/cancernetwork/bddc17c3dbfcdd80b813c5f7adab2352981fd88d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403712991112 https://www.cancernetwork.com/view/preparing-for-advanced-therapy-in-relapsed-refractory-multiple-myeloma2026-08-25https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403597332112 https://www.cancernetwork.com/view/managing-radiation-necrosis-is-next-frontier-in-stereotactic-radiosurgery2026-08-25https://cdn.sanity.io/images/0vv8moc6/cancernetwork/8509ad4f8c7c8f6c159a813daae4a72f1600479d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403661190112 https://www.cancernetwork.com/view/evolving-treatment-goals-in-relapsed-refractory-multiple-myeloma2026-08-25https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403599180112 https://www.cancernetwork.com/view/lenvatinib-combo-holds-ground-against-her2-adcs-in-endometrial-cancer2026-08-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9a0171c28c269af17813ee7081d782dc40d5e34f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403604218112 https://www.cancernetwork.com/view/expanding-indications-for-stereotactic-radiosurgery-in-brain-metastases2026-08-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/098a0081c18222eb49abf0f1f6097e7b41a86d48-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403661007112 https://www.cancernetwork.com/view/quality-of-life-subgroup-consistency-and-the-keynote-966-study-design2026-08-24https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c7a8b7d8cc2f7826679acabaa26445fe9d8d8d2-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403336646112 https://www.cancernetwork.com/view/rethinking-clinical-trial-design-to-include-patients-with-brain-metastases2026-08-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/85a535f9ae53e1cf3d38447338765e9b3a05998b-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403811988112 https://www.cancernetwork.com/view/how-fluorescent-tracers-could-transform-lung-cancer-surgery2026-08-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/49faf0df44911acce2186795c99cff91b78c46df-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403727847112 https://www.cancernetwork.com/view/platinum-free-interval-does-not-predict-io-response-in-endometrial-cancer2026-08-23https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d491cccde8a163525300d20bf7cfbd78ce0a6b31-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403605073112 https://www.cancernetwork.com/view/weighing-real-world-data-vs-clinical-trials-for-nalirifox-in-pdac2026-08-22https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ca7a454cff3b1702d28520e341961e52297e5976-1688x950.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403721186112 https://www.cancernetwork.com/view/five-year-keynote-775-data-confirm-durable-benefit-with-lenvatinib-combo2026-08-22https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9ea4ac50ff74b1e4f844e8aaa1d6352413115486-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403604802112 https://www.cancernetwork.com/view/her2-neu-conversion-rates-make-retesting-essential-in-gyn-cancers2026-08-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/a44863b7ae200a806e201bcac9d536b0fffedbd7-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403715434112 https://www.cancernetwork.com/view/lymphoma-s-revolution-evens-rhodes-on-cll-car-t-and-nj-care2026-08-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b7e524637b161b890d553053fced81152eebd803-1280x720.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403768874112 https://www.cancernetwork.com/view/managing-diarrhea-and-optimizing-dose-reductions-with-nalirifox2026-08-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ca7a454cff3b1702d28520e341961e52297e5976-1688x950.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403719948112 https://www.cancernetwork.com/view/debating-locoregional-versus-earlier-systemic-therapy-in-bclc-b-hcc2026-08-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cabf8c772800a6812c20411dc26c291b2ee759d7-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6399917165112 https://www.cancernetwork.com/view/debating-frontline-treatment-for-child-pugh-b7-disease-with-compromised-liver-function2026-08-21https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cabf8c772800a6812c20411dc26c291b2ee759d7-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6399917653112 https://www.cancernetwork.com/view/lenvatinib-pembrolizumab-shows-promise-after-io-progression-in-gyn-cancers2026-08-20https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f093ac3b813df56255dc332261d8dfb503e81568-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403606448112 https://www.cancernetwork.com/view/choosing-between-approved-frontline-metastatic-pancreatic-cancer-regimens2026-08-20https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ca7a454cff3b1702d28520e341961e52297e5976-1688x950.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403719947112 https://www.cancernetwork.com/view/who-are-the-key-candidates-to-receive-subcutaneous-amivantamab-for-hnscc-2026-08-19https://cdn.sanity.io/images/0vv8moc6/cancernetwork/86086b39c9a601d45e4ceb6af81b39e2331d9eb9-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403600297112 https://www.cancernetwork.com/view/expert-discussion-on-earlier-use-of-teclistamab-based-therapy-in-relapsed-refractory-multiple-myeloma2026-08-19https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402777549112 https://www.cancernetwork.com/view/weighing-bispecific-antibodies-against-car-t-cells-in-multiple-myeloma2026-08-19https://cdn.sanity.io/images/0vv8moc6/cancernetwork/6297a7f434989295e7d0d3795121ccf7cf4b7757-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403405724112 https://www.cancernetwork.com/view/majestec-3-evaluates-teclistamab-plus-daratumumab-in-relapsed-refractory-multiple-myeloma2026-08-19https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402775309112 https://www.cancernetwork.com/view/managing-subcutaneous-amivantamab-toxicities-in-head-and-neck-cancer2026-08-18https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d914c31e5aa3c003f4db291568f1acdcf1aaa899-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403598159112 https://www.cancernetwork.com/view/monitoring-educating-patients-on-tarlatamab-of-icans-and-crs-risk2026-08-18https://cdn.sanity.io/images/0vv8moc6/cancernetwork/5c87eee1d6563a4391bb2c3a4e685234834133fe-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403591813112 https://www.cancernetwork.com/view/bispecific-antibodies-are-advancing-into-earlier-line-multiple-myeloma2026-08-18https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ac06d114e7b33695f6c25df3dd1c20fcc1c570fe-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403403627112 https://www.cancernetwork.com/view/the-emotional-impact-of-relapsed-refractory-multiple-myeloma2026-08-18https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403597141112 https://www.cancernetwork.com/view/understanding-the-relapsed-refractory-multiple-myeloma-journey2026-08-18https://cdn.sanity.io/images/0vv8moc6/cancernetwork/ee2dcebb52338b07c0f0b1feb3d79bd789bdec59-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403596338112 https://www.cancernetwork.com/view/where-will-cell-and-gene-therapy-go-next-in-multiple-myeloma-2026-08-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/d27c7b9097be9db000a70df5add773b0a200a046-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402923105112 https://www.cancernetwork.com/view/how-tarlatamab-compares-with-cns-directed-chemo-radiation-in-sclc2026-08-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c564d8654abdeec31329856f3a2b95bc35e1d7bb-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403592013112 https://www.cancernetwork.com/view/topaz-1-study-design-and-long-term-overall-survival-outcomes2026-08-17https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3c7a8b7d8cc2f7826679acabaa26445fe9d8d8d2-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403337045112 https://www.cancernetwork.com/view/one-of-the-best-opportunities-for-long-term-remission-in-multiple-myeloma2026-08-16https://cdn.sanity.io/images/0vv8moc6/cancernetwork/66771ddad582df1a2df15d62063977ab11c786db-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402921549112 https://www.cancernetwork.com/view/defining-the-objectives-of-an-analysis-of-tarlatamab-in-brain-metastases2026-08-15https://cdn.sanity.io/images/0vv8moc6/cancernetwork/153aebd3f239f0d6da54014879209548df2b5591-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403461677112 https://www.cancernetwork.com/view/what-are-the-biggest-misconceptions-about-car-t-cells-in-multiple-myeloma-2026-08-15https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c0cd8a12a9161c5a818f0c250a9ea2c7fecdf721-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402923591112 https://www.cancernetwork.com/view/the-rationale-for-jak-inhibition-pd-1-blockade-in-immune-resistant-rcc2026-08-15https://cdn.sanity.io/images/0vv8moc6/cancernetwork/9c541bbf84fd717563c88d99a3739ede9d7e2e1a-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403229925112 https://www.cancernetwork.com/view/ensuring-access-to-car-t-cells-among-rural-multiple-myeloma-populations2026-08-14https://cdn.sanity.io/images/0vv8moc6/cancernetwork/65556d9bde96f6f23265b79c00ac483b6682726d-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402922312112 https://www.cancernetwork.com/view/debating-frontline-choice-for-child-pugh-a-bclc-c-bulky-disease2026-08-14https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cabf8c772800a6812c20411dc26c291b2ee759d7-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6399915180112 https://www.cancernetwork.com/view/timing-systemic-therapy-and-locoregional-treatment-in-intermediate-stage-hcc2026-08-14https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cabf8c772800a6812c20411dc26c291b2ee759d7-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6399918632112 https://www.cancernetwork.com/view/how-ai-and-health-networks-are-democratizing-clinical-trial-access2026-08-13https://cdn.sanity.io/images/0vv8moc6/cancernetwork/25cfe4ab041727752bc043794637cae61d429761-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403169268112 https://www.cancernetwork.com/view/monitoring-and-mitigating-emergent-toxicities-during-car-t-cell-therapy2026-08-13https://cdn.sanity.io/images/0vv8moc6/cancernetwork/601710f44bebe48535cb37ab7df37b2973c08ac1-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402922145112 https://www.cancernetwork.com/view/arnt-expression-patterns-hold-promise-for-hif-1-inhibition-in-rcc-subtypes2026-08-12https://cdn.sanity.io/images/0vv8moc6/cancernetwork/b3eb1f5585b31d0457a4348fe3d3dbc5bf33b0d4-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6403229734112 https://www.cancernetwork.com/view/bolstering-the-referral-process-for-car-t-cell-therapy-in-multiple-myeloma2026-08-12https://cdn.sanity.io/images/0vv8moc6/cancernetwork/13251dd8c46c9472160157d28b61a7a4180e566f-1920x1080.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402922313112 https://www.cancernetwork.com/view/expert-perspectives-on-sequencing-bcma-directed-therapies-in-relapsed-refractory-multiple-myeloma2026-08-12https://cdn.sanity.io/images/0vv8moc6/cancernetwork/50171b46bbf140c9a61bcc8068647893cf610187-886x498.pnghttps://players.brightcove.net/10203567001/dDZp7kuoR_default/index.html?videoId=6402776583112